EPISODE · Mar 17, 2025 · 19 MIN
How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.• The importance of patient characteristics and IMDC risk categorization in treatment decisions.• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.• The role of ctDNA, PD-L1 testing, and NGS in RCC.Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.YouTube: https://youtu.be/Bbv9N7-YKIMFollow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
What this episode covers
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.• The importance of patient characteristics and IMDC risk categorization in treatment decisions.• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.• The role of ctDNA, PD-L1 testing, and NGS in RCC.Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.YouTube: https://youtu.be/Bbv9N7-YKIMFollow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
NOW PLAYING
How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m